Opinion Factsheet  

Eine Arzneimittelstrategie für Europa und Legislativvorschlag zur Änderung des Mandats der Europäischen Arzneimittel-Agentur (EMA)

BGCSDADEELENESETFIFRHRHUITLTLVMTNLPLPTROSKSLSV
Opinion Number: CDR 5525/2020
Rapporteur: SACRÉDEUS Birgitta
Commission: NAT
Status: Under preparation
Date: 07/05/2021
 
to draw attention to the critical role played by the local and regional levels in countries' crisis preparedness and to the need to involve them in framing measures to strengthen security of supply of medicines and reduce vulnerability
to consider the objectives and the flagship initiatives of the pharmaceutical strategy from the local/regional point of view as the healthcare systems are decentralised to varying degrees in 19 of the 27 Member States and local and regional authorities are also involved in funding healthcare in many Member States
to ensure that the legal framework for the future European Health Union recognises local and regional authorities' responsibility for public health and builds on lessons learned from crises at the levels of governance closest to ordinary people
to consider whether the practical facilities are there for Member States to provide the EMA with the information requested, and whether the proposal creates excessive red tape for Member States and the healthcare system
The opinion will be discussed at the meeting of the CoR Interregional Group on Health and Wellbeing on 2 March. The speakers will include representatives of DG SANTE and EP ENVI Committee (tbc).

Rapporteur participating as panellist at
the EC DG EMPL/SEDEC commission webinar on ''The role of regions and cities in supporting apprenticeships, upskilling and reskilling in the health sector'' on 23 March
the EESC public hearing on "Building A European Health Union" on 29 March